27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a clinical-stage biopharmaceutical company developing novel nucleic acid-based product candidates for the treatment of cancer and rare diseases. The company is “capable of generating a host of promising drug candidates,” JMP Securities’ Michael King said in a report.
King initiated coverage of the company with a Market Outperform rating and price target of $8.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Idera Pharma was founded on the basis of pioneering work in the field of antisense oligonucleotides and has a “best-of-breed nucleic acid therapeutic platform” that could generate a large number of promising drug candidates, the analyst mentioned.
The company has entered into the immuno-oncology [IO] space, which is a strategic move. Its lead IO asset, IMO-2125, has exhibited “impressive clinical activity in combination with checkpoint inhibition in the setting of anti-PD-1 refractory metastatic melanoma,” King noted.
Related Link: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update
Key Positives
The analyst mentioned the following positives that combine to make Idera Pharma “an attractive investment opportunity in the small-cap biotech space”
- Innovative platform
- Strong scientific foundation
- Seasoned management team
- Assets with demonstrated clinical activity
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.